- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Acalabrutinib – March 2020
Acalabrutinib: Capsule 100 mg; Calquence®
Last updated
3 July 2020